- Hoodwinked: The blinkered perils of imaginary lifetime modeling in Type 2 Diabetes
- Without a Clue: The National Pharmaceutical Council and Imaginary Cost-Effectiveness Claims
3 thoughts on “Nothing to Cheer About: Endorsing Imaginary Economic Evaluations and Value Claims with Cheers 22”
Comments are closed.
Pingback: ASSUMPTIONS AND MODELS
Pingback: THE MYSTICAL VIRAL QALY
Pingback: TUFTS’ ORDINAL OVERSIGHT